Articles by Brandon Twyford
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
The study showed that favezelimab/pembrolizumab did not demonstrate a survival benefit over SOC.
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
The study shows the prognostic value of ctDNA in detecting MRD in patients with stage II/III CRC.
Trial results show no significant benefit of adding chemoradiation to adjuvant chemotherapy in resected gallbladder cancer.
SBRT shows promise for liver tumor control, but hepatobiliary toxicity remains a concern.
Atezolizumab plus bevacizumab shows promising efficacy and tolerability for advanced HCC with Child-Pugh B cirrhosis.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
The LEAP-012 study showed improved progression-free survival with lenvatinib, pembrolizumab, and TACE in HCC.
Combining encorafenib and cetuximab with FOLFIRI chemotherapy showed strong antitumor activity in BRAF V600E-mutant mCRC.
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
Results showed 64% of patients with HRD mPC were progression-free at 6 months with pembrolizumab and olaparib.
Cetuximab rechallenge guided by liquid biopsy improved response and disease control rates in RAS wild-type mCRC.
The US FDA recently granted approval for the combination of adagrasib and cetuximab for mCRC with KRAS G12C mutation.
[68Ga]Ga-RYZ-GPC3 shows high specificity in detecting hepatocellular carcinoma, outperforming conventional imaging.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.